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j ourna l homepage: www.e lsev ie r .com/ locate /atgReciprocity and transparency: Normative principles of data sharingThis is an interview with Dr. Jeantine Lunshof, Ethics Consultant to
the Personal Genome Project and the Center for Excellence in Genomic
Science, and Marie Curie Fellow, Harvard Medical School. Dr. Lunshof
researches conceptual and normative issues in systems and synthetic
biology. She has been a bioethics consultant to the Personal Genome
Project at the Genetics Department of Harvard Medical School (http://
www.personalgenomes.org) since 2006. Dr. Lunshof pioneered the con-
cept of ‘open consent’,1 entailing principles of veracity, reciprocity and
transparency, as applied to human genome research.
In many contexts, norms for information sharing are clear. Banks
share deposit, withdrawal and transaction data with account holders.
Digital data on a person's cell phone are assumed to be private and
not accessible to authorities without awarrant. Some companies collect
information about you, say Facebook or Amazon, and usually we decide
who to entrust our data with and who not to entrust. With genomic
data, the norms for sharing are arguably more complex and in some
cases contentious. Having been instrumental in developing the concept
of ‘open consent’ and implementing it in the Personal Genome Project
(PGP), I sat down with Dr. Jeantine Lunshof to discuss her views on
data and knowledge sharing.
1. The Human Genome Project spurred thinking about the features
of genetic/genomic data. Is human genetic data different than other
types of scientiﬁc data?
JL: Human genetic/genomic data is not like, for example, physics
data in an important way. Physics data, such as data generated by parti-
cle colliders or data from the Hubble Space Telescope, is generated by a
source that is natural phenomenon or thing. The data source in human
genetics is always a person and therein lies the fundamental difference.
If you describe your genetic data source, say a cohort, you're describing
the group of individuals, each of who havemorally relevant interests. In1 Lunshof, J.E., Chadwick, R., Vorhaus, D.B., Church, G.M. From genetic privacy to open
consent. Nature Reviews Genetics, 2008, 9:406–411.
http://dx.doi.org/10.1016/j.atg.2014.09.004physics, on the contrary, there are nodata sourceswithmorally relevant
interests.
2. Isn't anonymization of data the functional extraction of its person-
hood and so moral interests?
JL: Anonymization of human genomic data is not possible because
working with human biological material means that you are always
working with personal identiﬁers. Even if you claim that it is de-
identiﬁed so these persons have ‘disappeared’, we all know that that's
not true because a person's identity and interests are exactly in thema-
terial you're working with. Presuming anonymized human genomic
data could be managed in the same way as data from physics, or any
other non-human source, means ignoring the normative implications
of the interaction between researchers and participants. Reciprocity is
a key feature of human genomic data use. If one party is ignored then
by deﬁnition reciprocity does not exist. The principle of reciprocity re-
quires that people be told the truth about their biological materials.
The use of left over bodily materials and tissues in hospitals without
donor knowledge is an example of failed reciprocity. People should be
aware that research could be performed on their discarded samples,
data etc. In many places this is now disclosed, but many patients may
still not understand the full extent of this.
3. The notion of ‘open consent’ not only revolutionized theories of
clinical research ethics, but also paved the way for open sharing of
human genetic research data. At the heart of ‘open consent’ is the princi-
ple of veracity, which was not previously a primary requirement of con-
sent. How has ‘open consent’ permitted greater data sharing in the PGP?
JL: In applying the principle of ‘open consent’ to the PGP we deliber-
ately created a data sharing experiment.
First, let me explain the principle of veracity. We introduced the prin-
ciple of veracity— telling people the truth to the best of your knowledge
— to improve the quality and the validity of consent. Any biological mate-
rial is identiﬁable as such and we should tell this. Veracity is a necessary
pre-condition of autonomous decision-making and therefore a pre-
condition of consent. Nomatter how autonomous consent is, the consent
is not valid unless researchers have explained the truth about biological
data, namely that it is traceable to the source, which is after all a person.
Awareness of this, and the possibility that that person may be you, is in
my view the basis for valid consent. If someone cannot ﬁnd it acceptable
thatmaterial and information about themselveswill be available, the log-
ical consequence must be that they do not participate in research.
We applied the notion of ‘open consent’ in the PGP to demonstrate
how veracity and transparency function as a pre-condition of consent.
In the PGP, the consent process involves telling donors the truth, (that
is, to the best of our knowledge at that particular moment), about
their biospecimens, namely that their biological data contain identiﬁers,
even if the data is anonymized, which is not the case in our study.
Consenting individuals in this way is transparent. Donors are told that
neither we, nor other researchers, can control, over time, the chain of
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ple, that those researchers might use the data to make human–
animal chimeras or clones from your cell line. We tell donors this is a
possibility, even if it is a remote one. Consenting with veracity and
transparency involves telling donors we, as researchers, cannot guaran-
tee your privacy for all time, and the truth as we know it now may not
remain the same forever.
In the clinical context, however, the storage of someone's biological
material primarily is for documentation and the potential future beneﬁt
of that person. Most people will agree that their pathology sample can
be stored and used say 10 years later for their beneﬁt. But, specimens
obtained in the clinical context are also routinely being used for re-
search, so it is difﬁcult to separate research use from clinical use. It is im-
portant for people to know this.
The PGP's open consent asks donors if they agree to have their geno-
mic data out in the public and potentially open for everyone to see. This
means, that by deﬁnition, donors themselves have full access to their
data and discussions of returning selected data sub-sets are obsolete.
Finally, I believe that phenotype and medical data are far more sen-
sitive than genotype data.Medical data can bemuchmoremisused than
a genome sequence.
4. The Budapest Open Access Initiative launched 12 years ago with
the aim of making all new peer-reviewed research freely available on
the public Internet to anyone for lawful use. Today open access initia-
tives extend beyond published research to research data. As more and
more genetic/genomic data is generated the public is likely to gain
greater public interest. Ought anyone, say a gifted high school student,
who's interested in the data be able to access it for lawful use?
JL: The underlying framework for open access is egalitarian. In prin-
ciple, researchers and donors have equal rights to the data. Researchers
do not have a primarymoral claim to the data, apart from donors. This is
the theoretical concept. In practice, however, access is not equal. This is
true in both research and clinical contexts. In the latter, a classical exam-
ple of unequal rights is the so-called therapeutic exception in mental
health care, where patients may be barred from accessing their full
medical record. In the Netherlands, a recent study survey2 conducted
by the leading consumer organization found that 30 out of 50 surveyed
Primary Care Physicians (in the Netherlands the key keepers of patient
data) did not grant access to the patient participantswho requested it in
the course of this study. If you want full access, which is a legal right in
the Netherlands, youmay need to go to court. Internationally, in the re-
search setting, the procedures for data access may be bothersome as
well. There are data access committees that may uphold procedures
for accessing data. Smaller lesser-known institutions may not be able
to gain access the same way as a large established institution can.
Today, however, there is an overall trend towards greater openness
of research data. I think data generated by research that has been
funded by tax money should be prima facie available to anyone who
has interest in it,3 whether it is Hubble data or human genomic data.
The data itself should be available without a cost but there may be ap-
propriate costs involved in accessing it since investments are needed
to maintain the data. When you ask for samples from a biobank, the
specimen should be free but preparing and shipping it involves costs,
which should be paid by the user. Data sharing should be a not-for-
proﬁt enterprise.
Further, access to research data cannot always be unrestricted.
Biosafety and biosecurity needs constrain access and dissemination.
As researchers we have a responsibility to look at these limits. Even if
we favor making data open, responsible scientiﬁc conduct requires
protecting certain data from getting misused and causing serious
harm. While data from a diabetes study, for example, is unlikely tohttp://www.consumentenbond.nl/actueel/nieuws/2014/hoge-drempels-bij-opvragen-
medisch-dossier/.
3 Lunshof, J., Church, G, Prainsack, B, Raw Personal Data: Providing Access, Science 24
2014, vol. 343, 373–4. no. 6169.cause serious harm, information on high-risk pathogens can cause a ca-
tastrophe. The people who work on data and know it are best able to
make a judgment about the risk potential of that data. There are many
complex issues related to international sharing of data and this is
being addressed currently.
5. Why is sharing genetic/genomic data so important?
For several reasons. First, in order to operate as a science and a clinical
genetic practice you need a vast amount of data in order to align individ-
ual data to the reference data. In genomics research there is the sharing of
methods, sharing how you got the results, sharing the research questions
and outcomes of genomics projects. This sharing is not ethically problem-
atic because it concerns the research process in which sharing is neces-
sary for reproducing results and publishing. Secondly, in allowing open
access to research databases, that is to the researchmaterial, the availabil-
ity of all existing knowledge lets us avoid redoing studies. If negativeﬁnd-
ings are available, we do not need to conduct those studies again — at
least not in the same way — so we can avoid reinventing the wheel,
wasting scarce resources and unnecessarily burdening patients and re-
search volunteers. Thirdly, as I've said, people who are in studies should
know what information exchange in science means; they must under-
stand the concept of sharing, including the identiﬁability of their data.
6. How do you imagine that reciprocity could be established in
practice?
JL: I think you may be able to establish reciprocity in the ﬁrst contact
when an individual donates a specimen. I can imagine putting bar codes
on samples to enable tracking of them. People in IT tell me this can be
done. Even if only a minority of people want to see what happens to
their data, we need, nonetheless, a mechanism in place to make it possi-
ble for them to track their data if they choose to. Something like a courier
package tracking system would work. For example, blood is drawn from
you in a lab. The lab technician already has two stickers, one for the lab
requisition paper and another for the tube of blood. So, why not have a
third sticker to give to the donor? The technician could give you your
number and then you can track your sample online. Once the data is proc-
essed the situation gets more complicated and this is why in our Science
paper3 we argue that donors should have access to their raw data. In the
PGP, reciprocity does work indeed, because we have a direct relationship
with donors and, in principle, we can contact people whenever needed.
Similarly, donors can and do contact us. So, I think as the public becomes
more engaged I think open sharing under the conditions of veracity, rec-
iprocity and transparency could become more widespread.
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